https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/redirects.json
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/index
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/nav
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/related-studies
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-12/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-12/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-12/results
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-05/results
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-05/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-05/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-04/results
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-04/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-04/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-03/nav
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-03/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-03/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-03/conclusions
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-03/results/patient-demographics
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-03/results/patient-disposition
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-03/results/safety
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-03/results/efficacy
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-09/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-09/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-09/results
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-07/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-07/results
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-07/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-06/results
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-06/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-06/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-02/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-02/results
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-02/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-08/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-08/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-08/results
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/nav
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/introduction-RofeBookPro-2
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/conclusions
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/introduction-RofeBookPro
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/introduction-RofeBookPro-3
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/results/patient-demographics
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/results/efficacy-and-safety
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/results/patient-disposition
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/destiny-breast-01/results/further-analyses
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/dosing-and-admin-of-t-dxd
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/nav
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/t-dxd-ar-overview
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/aes-of-special-interest/embryo-fetal-toxicity
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/aes-of-special-interest/lv-dysfunction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/aes-of-special-interest/overview
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/aes-of-special-interest/neutropenia
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/aes-of-special-interest/ild-pneumonitis
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/other/alopecia
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/other/infusion-related-reactions
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/other/fatigue
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/gastrointestinal/decreased-appetite
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/gastrointestinal/diarrhea
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/gastrointestinal/nausea-and-vomiting
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/gastrointestinal/constipation
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/haematological/anaemia
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/adverse-reaction-management/ar-management/haematological/thrombocytopenia
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/ild/risk-in-patients
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/ild/case-study
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/ild/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/ild/monitoring-and-management
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/ild/nav
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/breast-cancer/ild/characteristics
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/related-study
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-rr/patient-disposition
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-rr/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-rr/patient-demographics
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-rr/nav
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-rr/summary
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-rr/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-rr/safety/general
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-rr/safety/cardiac
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-rr/efficacy/40-9-month-follow-up/additional-endpoints
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-rr/efficacy/40-9-month-follow-up/progression-free-survival
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/summary
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/patient-disposition
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/patient-demographics
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/study-design
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/study-design-modals
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/nav
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/introduction
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/efficacy/46-9-month-follow-up/progression-free-survival
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/efficacy/46-9-month-follow-up/additional-endpoints
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/efficacy/46-9-month-follow-up/progression-free-survival-modals
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/efficacy/46-9-month-follow-up/additional-endpoints-modals
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/efficacy/28-3-month-follow-up/progression-free-survival
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/efficacy/28-3-month-follow-up/patient-exposure
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/efficacy/28-3-month-follow-up/patient-exposure-modals
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/efficacy/28-3-month-follow-up/additional-endpoints
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/efficacy/28-3-month-follow-up/additional-endpoints-modals
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/safety/28-3-month-follow-up
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/safety/28-3-month-follow-up-modals
https://main--medicalcontent-astrazeneca--hlxsites.hlx.page/haematology/elevate-tn/safety/46-9-month-follow-up
